Here are four insights:
1. The preclinical study revealed the growth factor successfully encourages bone formation in a phylogenetically advanced spine model.
2. The rhNELL-1 growth factor did not cause inflammation and was well tolerated.
3. Bone Biologics plans to launch a pivotal animal study in mid-2018.
4. The company’s rhNELL-1 program is set for human trials in 2019.
More articles on biologics:
HSS’ Dr. Christopher Mendias earns $800k grant for stem cell research — 5 notes
Denver Bronco Derek Wolfe to undergo stem cell treatment after diagnosis from Dr. Robert Watkins — 3 things to know
How do muscle stem cells react to injury and aging? 6 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
